Participated in the podcast episode “The Converge IDE Trial”
As of 2022 · Last known relationship
Christian Shults is a cardiac surgeon and faculty leader whose work spans complex aortic disease, structural and valvular heart disease, coronary disease, and atrial fibrillation. MedStar Health identifies him as Scientific Lead for Cardiothoracic Surgery; its physician profile describes him as regional director of cardiac aortic surgery, surgical ablation, and innovation, fellowship director for the Complex Aortic Structural Heart Program, and assistant professor of surgery at Georgetown University School of Medicine. He earned his BS and MD from Georgetown, completed general surgery training at Washington Hospital Center, a research fellowship at Massachusetts General Hospital focused on hemorrhagic shock, and cardiothoracic training at Emory. He subsequently undertook visiting and advanced aortic and endovascular fellowships in Germany, Texas, and Arizona. He served as interim chair of Cardiac Surgery from 2019 to 2021.
Trained on the NeoChord device's use in Europe
Each topic is linked to its supporting source in Sources.
Training includes Participated in the podcast episode “The Converge IDE Trial”, Authored an article about personalized treatments for atrial fibrillation, Authored the video “Convergent Hybrid Ablation”, and Interim chair of Cardiac Surgery, plus 20 more records.
Explore education and training2025
As of 2022
As of 2021
As of 2021
As of 2021
As of 2018
As of 2017
As of 2013
As of 2013
As of 2010
As of 2004
As of 1997
Authored an article about a global study of the Thoraflex Hybrid frozen elephant trunk device for complex aortic arch disease[13]
2023
Convergent hybrid ablation procedure[9]
Enrollment in trials involving aortic endoprostheses, NeoChord mitral repair, Botox for atrial fibrillation, and transcatheter valve technologies[6]
Healthcare reform, healthcare economics, and innovations in minimally invasive or transcatheter therapies[6]
Novel treatment strategies for patients in hemorrhagic shock[6]
Principal investigator for the hospital's NeoChord clinical trial[7]
Treatment outcomes in complex aortic disease, valvular heart disease, atrial fibrillation, and coronary artery disease[6]